2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-129098
    DMHCA 79066-03-8 99.91%
    DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects?and can be used for the research of cholesterol homeostasis diabetes.
    DMHCA
  • HY-129380
    Fructosyl-lysine 21291-40-7
    Fructosyl-lysine (Fructoselysine) is an amadori glycation product from the reaction of glucose and lysine by the Maillard reaction. Fructosyl-lysine is the precursor to glucosepane, a lysine–arginine protein cross-link that can be an indicator in diabetes?detection.
    Fructosyl-lysine
  • HY-135035
    Decanoyl-L-carnitine 3992-45-8 ≥98.0%
    Decanoyl-L-carnitine has stimulatory effect on the formation of desaturated fatty acid metabolites from both [1-14C]-22:4 (n-6) and [1-14C]-22:5 (n-3).
    Decanoyl-L-carnitine
  • HY-19548A
    BEC hydrochloride 222638-67-7 ≥98.0%
    BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively.
    BEC hydrochloride
  • HY-E70131
    Endo H, Streptomyces picatus 37278-88-9
    Endo H, Streptomyces picatus (Endo-β-N-acetylglucosaminidase H), isolated from Streptomyces plicatus, hydrolyzes the central glycosidic bond of the β1, 4-di-N-acetylchitobiose core in asparagine-linked oligosaccharides.
    Endo H, Streptomyces picatus
  • HY-P3507A
    Dalazatide TFA 99.17%
    Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
    Dalazatide TFA
  • HY-108801A
    Aflibercept (VEGF Trap) 862111-32-8
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.
    Aflibercept (VEGF Trap)
  • HY-W008990
    Xanthosine 5'-monophosphate sodium salt 25899-70-1 ≥98.0%
    Xanthosine 5'-monophosphate sodium salt (5'-Xanthylic acid sodium salt) is an intermediate in purine metabolism. Xanthosine 5'-monophosphate sodium salt can be used for genetic code, nucleic acid structure, and DNA, RNA and protein synthesis research.
    Xanthosine 5'-monophosphate sodium salt
  • HY-13467
    AM-1638 1142214-62-7 99.65%
    AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC50 of 0.16 μM.
    AM-1638
  • HY-16100
    BI 99179 1291779-76-4 ≥98.0%
    BI 99179 is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats.
    BI 99179
  • HY-150069
    UBX1325 2271269-01-1 ≥98.0%
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR).
    UBX1325
  • HY-16007
    (-)-Hydroxycitric acid 27750-10-3 ≥98.0%
    (-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive and orally active inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss.
    (-)-Hydroxycitric acid
  • HY-34431
    Purine 120-73-0 ≥98.0%
    Purine is an endogenous metabolite. Purine bases are the building blocks of the nucleic acids. Purine inhibits the activation of PARP. Purine protects against oxidant-induced cell injury. Purine can be used in the research of cancer and nervous system diseases.
    Purine
  • HY-B0481
    Miglitol 72432-03-2 ≥98.0%
    Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets.
    Miglitol
  • HY-B0679
    Lubiprostone 136790-76-6 ≥98.0%
    Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research.
    Lubiprostone
  • HY-N0339
    Syringic acid 530-57-4 ≥98.0%
    Syringic acid is correlated with high antioxidant activity and inhibition of LDL oxidation.
    Syringic acid
  • HY-P4860
    Adropin (34-76) (human, mouse, rat) 1802086-30-1 99.92%
    Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway.
    Adropin (34-76) (human, mouse, rat)
  • HY-Y0262
    Oxalic acid, 99% 144-62-7 ≥98.0%
    Oxalic Acid is a strong dicarboxylic acid occurring in many plants and vegetables and can be used as an analytical reagent and general reducing agent.
    Oxalic acid, 99%
  • HY-Y0569
    D-Gluconic acid (solution) (51.205% in water) 526-95-4 ≥98.0%
    D-Gluconic acid is the carboxylic acid by the oxidation with antiseptic and chelating properties.
    D-Gluconic acid (solution) (51.205% in water)
  • HY-100793
    SR12813 126411-39-0 99.80%
    SR12813 (GW 485801) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM. SR12813 is also an efficient agonist of human pregnane X receptor (hPXR). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR).
    SR12813
Cat. No. Product Name / Synonyms Application Reactivity